Instead of an exclusive deal, Zymeworks shared its platform non-exclusively with multiple pharma giants. This multi-partner strategy validated the technology, generated capital, and built a portfolio of royalty interests before the company developed its own internal pipeline.

Unlike many biotech startups reliant on venture capital, Vivtex pursued a different path. By securing around 10 early pharma collaborations, the company generated a substantial stream of non-dilutive revenue, achieving profitability and financial independence far earlier than is typical.

Rather than inventing from scratch, InMedx licensed its advanced heart-rate variability algorithm from Omega Wave, a company serving pro sports teams. This allowed them to leverage a proven, precise technology and focus their resources on the higher-value activities of clinical validation and securing FDA clearance for medical use.

With no initial funding, CDR Life leveraged its team's expertise to develop and out-license an ophthalmology program. This non-dilutive deal with Boehringer Ingelheim provided the capital and validation needed to fund its primary mission in oncology and later secure a Series A round.

Instead of building a consumer brand from scratch, a technologically innovative but unknown company can license its core tech to an established player. This go-to-market strategy leverages the partner's brand equity and distribution to reach customers faster and validate the technology without massive marketing spend.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

While its internal pipeline targets oncology, LabGenius partners with companies like Sanofi to apply its ML-driven discovery platform to other therapeutic areas, such as inflammation. This strategy validates the platform's broad applicability while securing non-dilutive funding to advance its own assets towards the clinic.

Facing capital constraints, biotech companies must make a strategic choice. They can either dilute ownership by raising more venture capital or dilute their pipeline by partnering a secondary asset to fund their lead program. This "equity vs. assets" framework forces a clear-eyed decision on capital strategy.

For a biotech with an established commercial infrastructure, the most efficient growth strategy is to in-license late-stage or already-approved products. This leverages the existing sales force and operational teams to sell new products without adding significant overhead, maximizing operational efficiency and revenue.